Imunisasi AGE-BSA Mempengaruhi Kadar Glukosa Darah, AGE dan Antibodi Anti AGE Serum pada Mencit Diabetik Nefropati
Authors: Azizah Nurona , Mashitah Musthika Wida , Samsu Nur 
Published: November 2019

<p><em>Abstrak</em> <strong>-</strong> <strong>Diabetik nefropati </strong><strong>adalah</strong><strong> salah satu komplikasi serius dari diabetes melitus dan menjadi penyebab penting </strong><strong>dari </strong><strong>gagal ginjal stadium akhir. Salah satu kondisi hiperglikemia menyebabkan nefropati adalah melalui jalur pembentukan </strong><strong><em>Advanced Glycation End Products</em></strong><strong> </strong><strong>(</strong><strong>AGE</strong><strong>)</strong><strong>. Saat ini, terapi hanya berkisar obat-obatan anti-AGE yang harus dikonsumsi terus-menerus sehingga kurang efisien. Untuk itu, </strong><strong>imunisasi dapat menjadi</strong><strong> kandidat terapi </strong><strong>yang lebih baik</strong><strong>. </strong><strong>Penelitian ini mengamati efek imunisasi antigen AGE-BSA dalam menurunkan kadar gula darah, serum AGE, dan serum antibodi anti AGE. </strong><strong>Penelitian ini </strong><strong>menggunakan</strong><strong> desain <em>true experimental laboratory</em> dan metode <em>Randomized Posttest Only Control Group Design</em></strong><strong>. Mencit dibagi menjadi empat kelompok; Grup I mendapatkan PBS, Grup II diinjeksi STZ, Grup III diberikan imunisasi AGE-BSA, dan Grup IV diimunisasi AGE-BSA kemudian diinjeksi STZ. Penegakan diabetik nefropati apabila </strong><strong>glukosa darah pada Grup II </strong><strong>≥</strong><strong> 280 mg/dL. Dua belas minggu post injeksi STZ terakhir, kadar AGE dan antibodi anti AGE serum diukur menggunakan kit ELISA. Hasil menunjukkan jika imunisasi AGE-BSA secara signifikan menurunkan kadar glukosa darah dan AGE serum </strong><strong>(p = 0.000; p &lt; 0.05)</strong><strong>, namun meningkatkan secara signifikan kadar antibodi anti AGE serum </strong><strong>(p &lt; 0.05).</strong><strong> Sebagai tambahan, imunisasi AGE-BSA pada Grup III tidak menunjukkan perbedaan signifikan dengan mencit normal (Grup I), mengindikasikan imunisasi ini tergolong aman bagi variabel yang diukur. Kesimpulan dari penelitian ini adalah imunisasi AGE-BSA mampu menurunkan kadar glukosa darah dengan menghambat pembentukan AGE</strong><strong>.</strong></p><p><strong><em>Kata Kunci</em></strong> - <em>AGE-BSA,</em><em> </em><em>glukosa darah,</em><em> diabetik nefropati</em></p><p><em>Abstract</em> <strong>-</strong><strong> </strong><strong>Diabetic nephropathy is one of serious complication from diabetes mellitus and become vital cause of end-stage renal disease. One path how hyperglycemic condition causes nephropathy is through the formation of </strong><strong>Advanced Glycation End Products</strong><strong> </strong><strong>(</strong><strong>AGE</strong><strong>)</strong><strong>. Recently, therapies related AGE still use medicine only which need to be consumed </strong><strong>routinely</strong><strong> thus less effective. </strong><strong>Thus</strong><strong>, </strong><strong>immunization may be a</strong><strong> </strong><strong>better</strong><strong> candidate therapy. </strong><strong>We</strong><strong> </strong><strong>observed</strong><strong> the immunization effect using AGE-BSA antigen in </strong><strong>decreasing blood glucose, serum AGE, and anti-AGE antibody levels.</strong><strong> </strong><strong>This</strong><strong> </strong><strong>study </strong><strong>used</strong><strong> </strong><strong>true experimental laboratory </strong><strong>with</strong><strong> randomized post-test only contro</strong><strong>l</strong><strong> group </strong><strong>design. </strong><strong>Mice were randomly divided into four groups;</strong><strong> </strong><strong>Group l received PBS, Group II was given STZ, Group III was immunized </strong><strong>AGE-BSA, </strong><strong>Group IV was immunized AGE-BSA followed with STZ</strong><strong> injection</strong><strong>. </strong><strong>D</strong><strong>iabetic nephropathy </strong><strong>confirmed when blood glucose reached </strong><strong>≥</strong><strong> 280 mg/dL. Twelve</strong><strong> weeks post </strong><strong>last </strong><strong>STZ </strong><strong>injection</strong><strong>, the level of AGE and anti-AGE antibody from serum were measured using ELISA Kit. Result showed that </strong><strong>immunization</strong><strong> </strong><strong>of AGE-BSA </strong><strong>significantly decreased blood glucose and AGE level</strong><strong> </strong><strong>(p = 0.000; p &lt; 0.05) whereas, the level of anti-AGE antibody was significantly increased</strong><strong> in Group IV</strong><strong> </strong><strong>(p &lt; 0.05).</strong><strong> Additionally, immunization in Group III showed no any difference with Group I, indicating this immunization might be safe therapy for the variables measured.</strong><strong> </strong><strong>The conclusion of this research that</strong><strong> AGE-BSA immunization </strong><strong>is </strong><strong>able to decrease the level of blood glucose in diabetic nephropathy through inhibition of AGE formation.</strong> </p><p><strong><em>Keywords</em></strong><strong><em> </em></strong>- <em>AGE-BSA,</em><em> blood glucose</em><em>,</em><em> diabetic nephropathy</em></p>